课题基金 / 基金详情

BIOLOGIC CHARACTERIZATION OF A NOVEL SHC-LIKE GENE

BIOLOGIC CHARACTERIZATION OF A NOVEL SHC-LIKE GENE
新型 SHC 样基因的生物学特征
批准号:
2112751
负责人:
John P O'Bryan
金额:
$2.99万
依托单位国家:
美国
项目类别:
财政年份:
1995
资助国家:
美国
项目状态:
未结题
起止时间:
1995-12-20 至

项目摘要

项目成果

John P O'Bryan的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The ras oncogene encodes a small, molecular weight GTPase involved in a plethora of signaling pathways. Mutation of ras is a recurring theme in human malignancies. Approximately 30% of human tumors harbor mutant ras alleles with greater than 90% of pancreatic cancers positive for ras mutations. Therefore, understanding the regulation of the Ras signal is important for the design of potential therapeutic treatments of ras-positive tumors. Recently, a number of Ras regulatory proteins have been isolated. These include GTPase activating proteins (GAPs), guanine nucleotide exchange or releasing factors (GEFs) and adapter proteins such as Grb2 and Shc which link Ras to its upstream regulators. The objective of this proposal is to characterize a novel Shc-like gene (Sli) which I have recently identified and determine its role in the regulation of the Ras signal transduction cascade. The goals of this proposal are to (1) determine the similarities and differences between Sli and Shc in terms of their sequence and expression patterns; (2) determine the biochemical redundancy between Sli and Shc; (3) examine the role of Sli in transformation and differentiation; (4) examine the role of Sli in developmental processes through knocking out the gene by homologous recombination. The studies proposed here will begin to elucidate the function of a potentially novel Ras regulatory protein, Sli, furthering our understanding of Ras signaling. This, in turn, and may lead to a more rational design of therapeutic treatments for cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of novel Ras inhibitory agents for cancer therapy"
Development of novel RAS inhibitory agents for cancer therapy
Development of novel RAS inhibitory agents for cancer therapy
Novel Functions for Ras family GTPases
海外基金